



JPW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Abdennebi-Najar et al.

Serial No.: 10/828,817

Filed: April 21, 2004

For: GONADOTROPHINS IN PLANTS

Confirmation No.: 7701

Examiner: To be assigned

Group Art Unit: 1646

Attorney Docket No.: 2183-6625.1US

CERTIFICATE OF MAILING

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail on the date of deposit shown below with sufficient postage and in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

April 29, 2005
Date

Betty Vowles
Signature

Betty Vowles
Name (Type/Print)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08 be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

Pursuant to 37 C.F.R. § 1.98(d), a copy of any patent, publication or other information listed in the Information Disclosure Statement is not required to be provided if it was previously cited by or submitted to the office in a prior application, provided that the prior application is properly identified in the statement and relied upon for an earlier filing date under 35 U.S.C. § 120.

Serial No.: 10/828,817

Accordingly, no copy of information marked with a pound sign (#) is enclosed because it was previously cited or submitted to the patent office in a prior application which is properly identified above, and is relied upon for an earlier filing date. The references are as follows:

Foreign Patent Documents

<u>Document No.</u>	<u>Publication Date</u>	<u>Patentee</u>
#WO 01/31045 A1	05-03-2001	Stichting Dienst Landbouwkundig Onderzoek

Other Documents

#MASRI et al., Identification of the Full-Length Coding Sequence for Human Galactosyltransferase (B-N-Acetylglucosaminide: B1,4-Galactosyltransferase); Biochemical and Biophysical Research Communications, December 15, 1988, Biochemical and Biophysical Research Communications, pp. 657-63, Vol. 157, No. 2, Academic Press, Inc.


#WRIGHT et al., Abstract. Effect of glycosylation on antibody function: implications for genetic engineering, Trends in Biotechnology, January 1997, pp. 26-32, Vol. 15, Issue 1, Elsevier Ltd.

#Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are not being provided since they were previously cited by or submitted to the Office in the following prior application:
Serial No.: 10/133,205
Filed: April 29, 2005
For: GONADOTROPHINS IN PLANTS, which application is being relied upon for an earlier filing date under 35 U.S.C. § 120.

This Supplemental Information Disclosure Statement is believed to be filed before the mailing date of a first Office Action on the merits; therefore, no fee is due.

Serial No.: 10/828,817

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Andrew F. Nilles".

Andrew F. Nilles
Registration No. 47,825
Attorney for Applicant(s)
TRASKBRITT, P.C.
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922

Date: April 29, 2005
AFN/bv

Enclosures: Form PTO/SB/08
Copy of documents cited

Document in ProLaw



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/828,817
Filing Date	April 21, 2004
First Named Inventor	Abdennebi-Najar et al.
Group Art Unit	1646
Examiner Name	C. Collins
Attorney Docket Number	2183-6625.1US

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		#WO 01/31045 A1	05-03-2001	Stichting Dienst Landbouwkundig Onderzoek		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***(use as many sheets as necessary)*

Sheet

2

of

2

Complete if Known

Application Number

10/828,817

Filing Date

April 21, 2004

First Named Inventor

Abdennebi-Najar et al.

Group Art Unit

1646

Examiner Name

C. Collins

Attorney Docket Number

2183-6625.1US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		#MASRI et al., Identification of the Full-Length Coding Sequence for Human Galactosyltransferase (B-N-Acetylglucosaminide: B1,4-Galactosyltransferase); Biochemical and Biophysical Research Communications, December 15, 1988, Biochemical and Biophysical Research Communications, pp. 657-63, Vol. 157, No. 2, Academic Press, Inc.	
		#WRIGHT et al., Abstract. Effect of glycosylation on antibody function: implications for genetic engineering, Trends in Biotechnology, January 1997, pp. 26-32, Vol. 15, Issue 1, Elsevier Ltd.	

Examiner
Signature

Date

Considered

#Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are not being provided since they were previously cited by or submitted to the Office in the following prior application:

Serial No.: 10/133,205

Filed: April 29, 2005

For: GONADOTROPHINS IN PLANTS, which application is being relied upon for an earlier filing date under 35 U.S.C. § 120.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.